Rafferty Asset Management LLC Has $12.04 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Rafferty Asset Management LLC reduced its holdings in Alnylam Pharmaceuticals by 15.6%, owning 44,585 shares valued at approximately $12.04 million after selling 8,232 shares in the first quarter.
• Alnylam Pharmaceuticals saw an increase in stock price targets from various analysts, with JPMorgan Chase raising its target to $475.00 and Wells Fargo increasing it to $395.00.
• The company reported impressive earnings, posting an EPS of $0.32, which exceeded expectations, and saw a revenue increase of 17.3% year-over-year.

Rafferty Asset Management LLC lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 15.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,585 shares of the biopharmaceutical company's stock after selling 8,232 shares during the quarter. Rafferty Asset Management LLC's holdings in Alnylam Pharmaceuticals were worth $12,039,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at $27,000. Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $28,000. Whipplewood Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares in the last quarter. Bessemer Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Finally, Colonial Trust Co SC bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $35,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY traded down $5.82 during midday trading on Monday, hitting $446.51. The company had a trading volume of 827,614 shares, compared to its average volume of 1,190,821. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock has a market cap of $58.53 billion, a price-to-earnings ratio of -180.77 and a beta of 0.32. The firm has a fifty day simple moving average of $374.57 and a two-hundred day simple moving average of $303.25. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $469.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business's quarterly revenue was up 17.3% on a year-over-year basis. During the same period last year, the business posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Michael W. Bonney sold 11,250 shares of the firm's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $450.00, for a total value of $5,062,500.00. Following the sale, the director directly owned 16,804 shares in the company, valued at $7,561,800. This trade represents a 40.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the completion of the sale, the executive vice president owned 50,121 shares in the company, valued at $22,718,345.67. This represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,594 shares of company stock worth $25,551,456. 1.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on ALNY shares. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a report on Friday, August 1st. Oppenheimer upgraded shares of Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price on the stock in a report on Monday, August 4th. Chardan Capital lifted their target price on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Raymond James Financial assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They issued an "outperform" rating and a $370.00 target price on the stock. Finally, Morgan Stanley lifted their target price on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $405.33.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.